Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.

Our findings support the use of standard approved multi-agent therapy in rPDAC. Patients derive significant benefit from these standard combination therapies with median OS that is comparable to what is observed with treatment for de novo mPDAC.